OrbiMed is one of the world’s largest dedicated healthcare investment firms, headquartered in New York and active across venture, private equity, public markets, credit, and royalties. It invests across the full healthcare stack, from startups to public companies, and has enormous scale relative to most specialist investors. That breadth makes it one of the most influential capital providers in healthcare globally.

Its neuroscience relevance comes primarily through therapeutics, diagnostics, and medical devices tied to neurological disease, including companies focused on neurodegeneration. OrbiMed is not a pure neurotech specialist, but its scale and healthcare concentration make it a highly credible lead or co-investor for large, clinically oriented neuro rounds. It is especially relevant where companies operate in regulated, FDA-intensive pathways.

The firm invests globally across all major healthcare markets. For neurotech founders, OrbiMed is most relevant for clinical-stage companies that have substantial healthcare substance and financing needs. It is a major institutional player for late-seed through growth rounds where healthcare sophistication and large check size matter.